GATA2 and acute myeloid leukemia: Recently it has been reported that reduction of GATA2 by shRNA or the inhibitor K7174 sensitizes KG1a acute myeloid leukemia cells to chemotherapy [24], suggesting that suppression of GATA2 expression or inhibition of its transcriptional activity may have potential as an ancillary therapy in AML.